Advertisement for orthosearch.org.uk
Results 1 - 3 of 3
Results per page:
Bone & Joint Open
Vol. 2, Issue 11 | Pages 1004 - 1016
26 Nov 2021
Wight CM Whyne CM Bogoch ER Zdero R Chapman RM van Citters DW Walsh WR Schemitsch E

Aims

This study investigates head-neck taper corrosion with varying head size in a novel hip simulator instrumented to measure corrosion related electrical activity under torsional loads.

Methods

In all, six 28 mm and six 36 mm titanium stem-cobalt chrome head pairs with polyethylene sockets were tested in a novel instrumented hip simulator. Samples were tested using simulated gait data with incremental increasing loads to determine corrosion onset load and electrochemical activity. Half of each head size group were then cycled with simulated gait and the other half with gait compression only. Damage was measured by area and maximum linear wear depth.


Orthopaedic Proceedings
Vol. 102-B, Issue SUPP_8 | Pages 13 - 13
1 Aug 2020
Atrey A Wu J Waddell JP Schemitsch EH Khoshbin A Ward S Bogoch ER
Full Access

The purpose of this investigation is to assess the rate of wear the effect once the “bedding in period”/ poly creep had been eliminated. Creep is the visco-elastic deformation that polyethylene exhibits in the first 6–12 weeks. We also assessed the wear pattern of four different bearing couples in total hip arthroplasty (THA): cobalt-chrome (CoCr) versus oxidized zirconium (OxZir) femoral heads with ultra-high molecular weight polyethylene (UHMWPE) versus highly-crosslinked polyethylene (XLPE) acetabular liners.

This was a randomized control study involving 92 patients undergoing THA. They were randomized to one of four bearing couples: (1) CoCr/UHMWPE (n= 23), (2) OxZir/UHMWPE (n=21), (3) CoCr/XLPE (n=24), (4) OxZir/XLPE (n=24). Patients underwent a posterior approach from one of three surgeons involved in the study. All patients received a porous-coated cementless acetabular shell and a cylindrical proximally coated stem with 28 mm femoral heads. Each patient was reviewed clinically and radiographically at six weeks, three and 12 months, two, five and 10 years after surgery. Standardized anteroposterior and lateral radiographs were taken. All polyethylene wear was measured by an independent blinded reviewer. Linear and volumetric wear rates were measured on radiographs using a validated computer software (Polyware Rev. 5). Creep was defined as the wear at 6 or 12 weeks, depending on if there was a more than 10% difference between both measurements. If a greater than 10% difference occurred than the later period's wear would be defined as creep.

72 hips were included in analysis after exclusion of seven revisions, three deaths and 10 losses to follow-up. The annual linear wear rates (in mm/y) at 10 years were (1) 0.249, (2) 0.250, (3) 0.074 and (4) 0.050. After adjusting for creep these rates become were (1) 0.181, (2) 0.142, (3) 0.040 and (4) 0.023. There is statistical differences between raw and adjusted linear wear rates for all bearing couples. The percentage of the radiographically measured wear at 10 years due to creep is (1) 30% (2) 44%, (3) 58.5% and (4) 51.5% with significant differences in couples with XLPE versus those with UHMWPE. There was no significant correlation between age, gender, cup size, tilt, planar anteversion and the linear or volumetric wear rates.

The linear wear rate of both UHMWPE and XLPE are even lower thxdsxzan previously described when creep is factored out. XLPE has again demonstrated far superior linear wear rates at 10 years than UHMWPE. There were no significant differences in wear rate at 10 years between CoCr and OxZir, this may be due to an underpowered study. XLPE exhibits proportionally more creep than UHMWPE within the first 6–12 weeks and accounts for more of the total wear at 10 years as measured radiographically at the end period.


Orthopaedic Proceedings
Vol. 92-B, Issue SUPP_I | Pages 17 - 17
1 Mar 2010
Bogoch ER Elliot-Gibson V Wang R Josse R
Full Access

Purpose: We report the prevalence of vitamin D deficiency and other causes of secondary osteoporosis in a group of typical and atypical fragility fracture patients.

Method: A chart audit of 399 patients (117 males, mean age 64.6, SD 12.8; 282 females, mean age 63.5, SD 14.6) referred from an inner city orthopaedic unit to the Metabolic Bone Disease Clinic (MBDC) over a three-year period was conducted. Fracture locations and etiology: 90 hip (76 fragility), 161 wrist (135 fragility), 8 vertebral (6 fragility), 77 shoulder (62 fragility), 62 other sites (45 fragility), 1 both hip and shoulder (fragility).

Results: Thirty percent of patients (42 males, 78 females) had a total of 149 secondary causes of OP recorded. Secondary causes included medication use (oral steroids, anti-convulsants); rheumatic, gastrointestinal and endocrine conditions (RA, IBD, Graves disease, Type I DM, hyperparathyroidism); hypogonadal states (premature ovarian failure, hypogonadism); genetic conditions (hypophosphatasia); hematological conditions (thalassemia); miscellaneous causes (smoking, renal impairment). A total of 308 patients completed blood work, including 269 patients who had a 25-OH vitamin D measurement: 7 patients were deficient at ≤ 25 nmol/l, 137 were insufficient at 26 to 74 nmol/l, and 125 were sufficient at ≥ 75nmol/l. There were no differences between males and females (p = 0.457), or among fracture locations (p 0.246). Over 75% of blood/urine analyses were within the normal range for: 1,25 vitamin D, ALP, ALT, AST, bilirubin, creatinine, T3, T4, homocysteine, magnesium, phosphorus, platelets, serum calcium, protein, albumin, globulin, TSH, tissue transglutaminase, Vit B12, WBC, 24 hour urine calcium and phosphorus. Between 50 and 74% of the blood/urine analyses were within the normal range for: CRP (n = 30; 30% elevated), ESR (n = 173; 43% elevated), testosterone (n = 53; 25% of men below normal), bioavailable testosterone (n = 52; 40% of men below normal), N- telopeptide (n = 5; 30% of women elevated), RBC folate (n = 12; 33% elevated), 24 hour urine creatinine (n = 51; 27% below normal).

Conclusion: Half of the fracture patients were vitamin D insufficient. A standardized blood test protocol for all fragility fracture patients is in use.